ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 572,74
-0,79%
Dow Jones
40 211,72
0,00%
DAX
18 493,37
-0,57%
Brent Oil
83,065
-1,51%
Bitcoin
64 024,61
-1,29%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
01/11/201921h30PR Newswire (US)Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
28/10/201914h00PR Newswire (US)Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in ...NASDAQ:PTLAPortola Pharmaceuticals Inc
15/10/201914h30PR Newswire (US)Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019NASDAQ:PTLAPortola Pharmaceuticals Inc
02/10/201922h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
02/10/201922h17Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/09/201912h33Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
19/09/201914h20PR Newswire (US)Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of DirectorsNASDAQ:PTLAPortola Pharmaceuticals Inc
22/08/201914h30PR Newswire (US)Portola Pharmaceuticals to Participate in Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
14/08/201922h15Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTLAPortola Pharmaceuticals Inc
14/08/201901h32PR Newswire (US)Portola Pharmaceuticals Announces Pricing of Public Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
12/08/201922h43PR Newswire (US)Portola Pharmaceuticals Announces Proposed Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
07/08/201923h16Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/08/201923h12Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/08/201922h32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/08/201922h05PR Newswire (US)Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
06/08/201914h30PR Newswire (US)Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in EuropeNASDAQ:PTLAPortola Pharmaceuticals Inc
05/08/201913h00PR Newswire (US)U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portol...NASDAQ:PTLAPortola Pharmaceuticals Inc
17/07/201914h30PR Newswire (US)Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019NASDAQ:PTLAPortola Pharmaceuticals Inc
08/07/201914h30PR Newswire (US)Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) ...NASDAQ:PTLAPortola Pharmaceuticals Inc
19/06/201917h05PR Newswire (US)Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re...NASDAQ:PTLAPortola Pharmaceuticals Inc
22/05/201916h45GlobeNewswire Inc.Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® i...NASDAQ:PTLAPortola Pharmaceuticals Inc
08/05/201914h01GlobeNewswire Inc.Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
26/04/201920h00GlobeNewswire Inc.European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t...NASDAQ:PTLAPortola Pharmaceuticals Inc
24/04/201914h30GlobeNewswire Inc.Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Developm...NASDAQ:PTLAPortola Pharmaceuticals Inc
22/04/201912h03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
22/04/201912h03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
17/04/201922h15GlobeNewswire Inc.Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019NASDAQ:PTLAPortola Pharmaceuticals Inc
10/04/201914h30GlobeNewswire Inc.New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust,...NASDAQ:PTLAPortola Pharmaceuticals Inc
20/03/201922h00GlobeNewswire Inc.Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of DirectorsNASDAQ:PTLAPortola Pharmaceuticals Inc
06/03/201922h10GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

BIT
P22SO0
NLBNPIT22SO0 20241220 800
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés